<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00306631</url>
  </required_header>
  <id_info>
    <org_study_id>MKC-101</org_study_id>
    <nct_id>NCT00306631</nct_id>
  </id_info>
  <brief_title>A Study to Determine the Antitumor Activity and Evaluate the Safety of MKC-1</brief_title>
  <official_title>A Phase 2 Study of Oral MKC-1 Administered Twice Daily for 14 Consecutive Days Every 4 Weeks in Patients With Advanced or Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CASI Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CASI Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase 2 study will determine the antitumor activity, based on the objective rate, of&#xD;
      oral MKC-1, administered twice daily for 14 consecutive days every 4 weeks, in patients with&#xD;
      advanced or metastatic breast carcinoma. The study will also evaluate the safety and response&#xD;
      duration in patients, time to tumor progression, and overall survival in patients following&#xD;
      MKC-1 therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Antitumor activity, based on the objective response rate</measure>
    <time_frame>every 8 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MKC-1</intervention_name>
    <description>Oral capsules, 30 mg and 100 mg capsule strengths; administered twice daily for 14 days in a 28 day cycle</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed advanced or metastatic adenocarcinoma of the&#xD;
             breast&#xD;
&#xD;
          -  18 years or older&#xD;
&#xD;
          -  Karnofsky performance status greater than or equal to 70%&#xD;
&#xD;
          -  Radiographic or physical examination evidence of at least one site of&#xD;
             unidimensionally-measurable disease, using the Response Evaluation Criteria in Solid&#xD;
             Tumors (RECIST) criteria&#xD;
&#xD;
          -  Must have failed both a taxane and an anthracycline, given sequentially or in&#xD;
             combination, either in an adjuvant or metastatic setting&#xD;
&#xD;
          -  All acute toxicity of any prior chemotherapy, surgery or radiotherapy must have&#xD;
             resolved to National Cancer Institute Common Toxicity Criteria (NCI CTC) Grade less&#xD;
             than or equal to 1&#xD;
&#xD;
          -  Lab results, within 10 days of MKC-1 administration:&#xD;
&#xD;
               -  Hemoglobin less than or equal to 9 g/dL&#xD;
&#xD;
               -  Absolute neutrophil count greater than or equal to 1.5 x 10^9/L&#xD;
&#xD;
               -  Platelet count greater than or equal to 75 x 10^9/L&#xD;
&#xD;
               -  Serum creatinine less than or equal to 1.5 x ULN (upper limit of normal)&#xD;
&#xD;
               -  AST less than or equal to 2.5 x ULN&#xD;
&#xD;
               -  Serum albumin greater than or equal to LLN (lower limit of normal)&#xD;
&#xD;
               -  Total bilirubin less than or equal to ULN&#xD;
&#xD;
               -  Alkaline phosphatase less than or equal to 2.5 x ULN&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pre-existing hepatomegaly with disease measures greater than or equal to 2 cm below&#xD;
             the costal margin, secondary to malignancy&#xD;
&#xD;
          -  Administration of cancer specific therapy within the following periods prior to study&#xD;
             drug initiation:&#xD;
&#xD;
               -  chemotherapy less than 3 weeks prior&#xD;
&#xD;
               -  hormonal therapy less than one week prior&#xD;
&#xD;
               -  radiation therapy less than 2 weeks prior&#xD;
&#xD;
          -  Be pregnant or lactating; not employing effective birth control&#xD;
&#xD;
          -  Known central nervous system (CNS) metastases unless treated, clinically stable and&#xD;
             not requiring steroids&#xD;
&#xD;
          -  Clinical evidence of bowel obstruction, active uncontrolled malabsorption syndromes or&#xD;
             a history of total gastrectomy&#xD;
&#xD;
          -  Administration of any investigational agent (therapeutic or diagnostic) within 4 weeks&#xD;
             prior to receipt of study medication&#xD;
&#xD;
          -  Uncontrolled hypercalcemia (serum calcium-corrected greater than 12 mg/dL)&#xD;
&#xD;
          -  Serious cardiac condition&#xD;
&#xD;
          -  Any medical conditions that, in the investigator's opinion would impose excessive risk&#xD;
             to the patient&#xD;
&#xD;
          -  Patients with previous malignancies unless free of recurrence for at least 5 years&#xD;
             except basal cell carcinoma of the skin or carcinoma-in-situ of the uterine cervix&#xD;
&#xD;
          -  Treatment with antiretroviral therapy metabolized through CYP3A4&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>IUPUI</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2009</verification_date>
  <study_first_submitted>March 22, 2006</study_first_submitted>
  <study_first_submitted_qc>March 22, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2006</study_first_posted>
  <last_update_submitted>June 2, 2009</last_update_submitted>
  <last_update_submitted_qc>June 2, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 3, 2009</last_update_posted>
  <responsible_party>
    <name_title>Carolyn Sidor, Chief Medical Officer</name_title>
    <organization>Miikana Therapeutics, an EntreMed Company</organization>
  </responsible_party>
  <keyword>Advanced and Metastatic Breast Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

